Which has better earnings & valuation, SIBN or QTRX?

SiBone has higher revenue and earnings than Quanterix. SiBone is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 4.24 -$18.90M -$0.34 N/A Quanterix $138.90M 0.90 -$107.15M -$2.63 N/A

Is SIBN or QTRX more profitable?

SiBone has a net margin of -6.85% compared to Quanterix's net margin of -80.25%. SiBone's return on equity of -8.23% beat Quanterix's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -6.85% -8.23% -6.07% Quanterix -80.25% -26.09% -19.03%

Does the media favor SIBN or QTRX?

In the previous week, SiBone had 4 more articles in the media than Quanterix. MarketBeat recorded 6 mentions for SiBone and 2 mentions for Quanterix. Quanterix's average media sentiment score of 0.94 beat SiBone's score of 0.66 indicating that Quanterix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quanterix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is QTRX or DNA more profitable?

Quanterix has a net margin of -80.25% compared to Ginkgo Bioworks' net margin of -259.96%. Quanterix's return on equity of -26.09% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Quanterix -80.25% -26.09% -19.03% Ginkgo Bioworks -259.96% -60.27% -26.88%

Does the media prefer QTRX or DNA?

In the previous week, Ginkgo Bioworks had 2 more articles in the media than Quanterix. MarketBeat recorded 4 mentions for Ginkgo Bioworks and 2 mentions for Quanterix. Quanterix's average media sentiment score of 0.94 beat Ginkgo Bioworks' score of 0.57 indicating that Quanterix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quanterix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PACB or QTRX?

In the previous week, Pacific Biosciences of California had 2 more articles in the media than Quanterix. MarketBeat recorded 4 mentions for Pacific Biosciences of California and 2 mentions for Quanterix. Pacific Biosciences of California's average media sentiment score of 1.15 beat Quanterix's score of 0.94 indicating that Pacific Biosciences of California is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacific Biosciences of California 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quanterix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TKNO or QTRX more profitable?

Alpha Teknova has a net margin of -38.37% compared to Quanterix's net margin of -80.25%. Alpha Teknova's return on equity of -24.94% beat Quanterix's return on equity. Company Net Margins Return on Equity Return on Assets Alpha Teknova -38.37% -24.94% -16.53% Quanterix -80.25% -26.09% -19.03%

Does the media refer more to TKNO or QTRX?

In the previous week, Alpha Teknova and Alpha Teknova both had 2 articles in the media. Quanterix's average media sentiment score of 0.94 beat Alpha Teknova's score of 0.93 indicating that Quanterix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Teknova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quanterix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to QTRX or SLP?

In the previous week, Simulations Plus had 3 more articles in the media than Quanterix. MarketBeat recorded 5 mentions for Simulations Plus and 2 mentions for Quanterix. Simulations Plus' average media sentiment score of 1.45 beat Quanterix's score of 0.94 indicating that Simulations Plus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quanterix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Simulations Plus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Quanterix (QTRX) Competitors

$2.64 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Compare

QTRX vs. SIBN, DNA, PACB, TKNO, and SLP

Should you buy Quanterix stock or one of its competitors? Quanterix's main competitors and comparable companies include SiBone (SIBN), Ginkgo Bioworks (DNA), Pacific Biosciences of California (PACB), Alpha Teknova (TKNO), and Simulations Plus (SLP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Quanterix compare to SiBone?

SiBone (NASDAQ:SIBN) and Quanterix (NASDAQ:QTRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

98.1% of SiBone shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 1.5% of Quanterix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

SiBone has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Quanterix has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

SiBone has higher revenue and earnings than Quanterix. SiBone is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	4.24	-$18.90M	-$0.34	N/A
Quanterix	$138.90M	0.90	-$107.15M	-$2.63	N/A

In the previous week, SiBone had 4 more articles in the media than Quanterix. MarketBeat recorded 6 mentions for SiBone and 2 mentions for Quanterix. Quanterix's average media sentiment score of 0.94 beat SiBone's score of 0.66 indicating that Quanterix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quanterix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SiBone has a net margin of -6.85% compared to Quanterix's net margin of -80.25%. SiBone's return on equity of -8.23% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
Quanterix	-80.25%	-26.09%	-19.03%

SiBone currently has a consensus price target of $24.17, suggesting a potential upside of 25.80%. Quanterix has a consensus price target of $3.00, suggesting a potential upside of 13.64%. Given SiBone's stronger consensus rating and higher possible upside, equities analysts clearly believe SiBone is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

SiBone beats Quanterix on 13 of the 16 factors compared between the two stocks.

How does Quanterix compare to Ginkgo Bioworks?

Quanterix (NASDAQ:QTRX) and Ginkgo Bioworks (NYSE:DNA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Quanterix currently has a consensus price target of $3.00, suggesting a potential upside of 13.64%. Ginkgo Bioworks has a consensus price target of $7.00, suggesting a potential upside of 0.29%. Given Quanterix's stronger consensus rating and higher possible upside, equities research analysts plainly believe Quanterix is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Quanterix has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market.

In the previous week, Ginkgo Bioworks had 2 more articles in the media than Quanterix. MarketBeat recorded 4 mentions for Ginkgo Bioworks and 2 mentions for Quanterix. Quanterix's average media sentiment score of 0.94 beat Ginkgo Bioworks' score of 0.57 indicating that Quanterix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quanterix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ginkgo Bioworks	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quanterix has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90M	0.90	-$107.15M	-$2.63	N/A
Ginkgo Bioworks	$170.15M	2.76	-$312.76M	-$5.01	N/A

86.5% of Quanterix shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 1.5% of Quanterix shares are held by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Quanterix has a net margin of -80.25% compared to Ginkgo Bioworks' net margin of -259.96%. Quanterix's return on equity of -26.09% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-80.25%	-26.09%	-19.03%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

Summary

Quanterix beats Ginkgo Bioworks on 10 of the 15 factors compared between the two stocks.

How does Quanterix compare to Pacific Biosciences of California?

Pacific Biosciences of California (NASDAQ:PACB) and Quanterix (NASDAQ:QTRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

86.5% of Quanterix shares are owned by institutional investors. 3.7% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 1.5% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Quanterix has lower revenue, but higher earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	2.72	-$546.38M	-$0.43	N/A
Quanterix	$138.90M	0.90	-$107.15M	-$2.63	N/A

Quanterix has a net margin of -80.25% compared to Pacific Biosciences of California's net margin of -82.49%. Quanterix's return on equity of -26.09% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%
Quanterix	-80.25%	-26.09%	-19.03%

Pacific Biosciences of California has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market. Comparatively, Quanterix has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Pacific Biosciences of California presently has a consensus target price of $1.83, suggesting a potential upside of 30.95%. Quanterix has a consensus target price of $3.00, suggesting a potential upside of 13.64%. Given Pacific Biosciences of California's stronger consensus rating and higher possible upside, equities research analysts clearly believe Pacific Biosciences of California is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Pacific Biosciences of California had 2 more articles in the media than Quanterix. MarketBeat recorded 4 mentions for Pacific Biosciences of California and 2 mentions for Quanterix. Pacific Biosciences of California's average media sentiment score of 1.15 beat Quanterix's score of 0.94 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quanterix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pacific Biosciences of California beats Quanterix on 10 of the 16 factors compared between the two stocks.

How does Quanterix compare to Alpha Teknova?

Alpha Teknova (NASDAQ:TKNO) and Quanterix (NASDAQ:QTRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Alpha Teknova has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Quanterix has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 13.2% of Alpha Teknova shares are held by company insiders. Comparatively, 1.5% of Quanterix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Alpha Teknova and Alpha Teknova both had 2 articles in the media. Quanterix's average media sentiment score of 0.94 beat Alpha Teknova's score of 0.93 indicating that Quanterix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Teknova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quanterix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alpha Teknova has a net margin of -38.37% compared to Quanterix's net margin of -80.25%. Alpha Teknova's return on equity of -24.94% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-38.37%	-24.94%	-16.53%
Quanterix	-80.25%	-26.09%	-19.03%

Alpha Teknova currently has a consensus price target of $7.50, suggesting a potential upside of 5.34%. Quanterix has a consensus price target of $3.00, suggesting a potential upside of 13.64%. Given Quanterix's higher possible upside, analysts plainly believe Quanterix is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Alpha Teknova has higher earnings, but lower revenue than Quanterix. Alpha Teknova is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	9.42	-$17.26M	-$0.31	N/A
Quanterix	$138.90M	0.90	-$107.15M	-$2.63	N/A

Summary

Alpha Teknova beats Quanterix on 9 of the 15 factors compared between the two stocks.

How does Quanterix compare to Simulations Plus?

Quanterix (NASDAQ:QTRX) and Simulations Plus (NASDAQ:SLP) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Simulations Plus has a net margin of 9.88% compared to Quanterix's net margin of -80.25%. Simulations Plus' return on equity of 13.50% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-80.25%	-26.09%	-19.03%
Simulations Plus	9.88%	13.50%	12.45%

Simulations Plus has lower revenue, but higher earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90M	0.90	-$107.15M	-$2.63	N/A
Simulations Plus	$79.18M	4.70	-$64.72M	$0.40	45.98

Quanterix has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Simulations Plus has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

Quanterix currently has a consensus target price of $3.00, indicating a potential upside of 13.64%. Simulations Plus has a consensus target price of $17.25, indicating a potential downside of 6.20%. Given Quanterix's higher possible upside, analysts plainly believe Quanterix is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

In the previous week, Simulations Plus had 3 more articles in the media than Quanterix. MarketBeat recorded 5 mentions for Simulations Plus and 2 mentions for Quanterix. Simulations Plus' average media sentiment score of 1.45 beat Quanterix's score of 0.94 indicating that Simulations Plus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quanterix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Simulations Plus	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.5% of Quanterix shares are owned by institutional investors. Comparatively, 78.1% of Simulations Plus shares are owned by institutional investors. 1.5% of Quanterix shares are owned by insiders. Comparatively, 19.1% of Simulations Plus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Simulations Plus beats Quanterix on 12 of the 15 factors compared between the two stocks.

Get Quanterix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QTRX vs. The Competition

Export

Metric	Quanterix	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$124.85M	$10.11B	$7.21B	$12.90B
Dividend Yield	N/A	1.46%	2.54%	11.28%
P/E Ratio	-1.00	50.44	212.62	21.91
Price / Sales	0.90	111.84	625.86	92.63
Price / Cash	N/A	26.70	28.74	36.03
Price / Book	0.42	5.49	11.08	6.36
Net Income	-$107.15M	$56.67B	$3.48B	$349.79M
7 Day Performance	-11.71%	-1.52%	0.13%	-0.80%
1 Month Performance	-25.00%	7.21%	7.08%	4.13%
1 Year Performance	-41.98%	24.31%	24.67%	15.17%

Quanterix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QTRX Quanterix	1.3531 of 5 stars	$2.64 flat	$3.00 +13.6%	-42.0%	$124.85M	$138.90M	N/A	460
SIBN SiBone	2.373 of 5 stars	$19.47 -2.5%	$24.17 +24.1%	+15.2%	$885.21M	$200.93M	N/A	350	Insider Trade
DNA Ginkgo Bioworks	0.9328 of 5 stars	$6.79 -8.3%	$7.00 +3.2%	-45.1%	$498.32M	$170.15M	N/A	640	Positive News Gap Down
PACB Pacific Biosciences of California	2.1577 of 5 stars	$1.28 -5.2%	$1.83 +43.2%	+6.9%	$419.62M	$160.01M	N/A	730	Analyst Downgrade
TKNO Alpha Teknova	1.5403 of 5 stars	$7.34 -0.3%	$7.50 +2.2%	+64.8%	$394.60M	$40.52M	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QTRX) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quanterix (QTRX) Competitors

QTRX vs. SIBN, DNA, PACB, TKNO, and SLP

How does Quanterix compare to SiBone?

Summary

How does Quanterix compare to Ginkgo Bioworks?

Summary

How does Quanterix compare to Pacific Biosciences of California?

Summary

How does Quanterix compare to Alpha Teknova?

Summary

How does Quanterix compare to Simulations Plus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTRX vs. The Competition

Quanterix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quanterix (QTRX) Competitors

QTRX vs. SIBN, DNA, PACB, TKNO, and SLP

How does Quanterix compare to SiBone?

Do insiders and institutionals have more ownership in SIBN or QTRX?

Which has more risk & volatility, SIBN or QTRX?

Which has better earnings & valuation, SIBN or QTRX?

Does the media favor SIBN or QTRX?

Is SIBN or QTRX more profitable?

Do analysts prefer SIBN or QTRX?

Summary

How does Quanterix compare to Ginkgo Bioworks?

Do analysts recommend QTRX or DNA?

Which has more risk & volatility, QTRX or DNA?

Does the media prefer QTRX or DNA?

Which has preferable valuation and earnings, QTRX or DNA?

Do institutionals and insiders have more ownership in QTRX or DNA?

Is QTRX or DNA more profitable?

Summary

How does Quanterix compare to Pacific Biosciences of California?

Do insiders and institutionals hold more shares of PACB or QTRX?

Which has stronger valuation and earnings, PACB or QTRX?

Is PACB or QTRX more profitable?

Which has more risk & volatility, PACB or QTRX?

Do analysts rate PACB or QTRX?

Does the media prefer PACB or QTRX?

Summary

How does Quanterix compare to Alpha Teknova?

Which has more risk and volatility, TKNO or QTRX?

Do institutionals and insiders believe in TKNO or QTRX?

Does the media refer more to TKNO or QTRX?

Is TKNO or QTRX more profitable?

Do analysts recommend TKNO or QTRX?

Which has preferable earnings and valuation, TKNO or QTRX?

Summary

How does Quanterix compare to Simulations Plus?

Is QTRX or SLP more profitable?

Which has stronger valuation and earnings, QTRX or SLP?

Which has more volatility and risk, QTRX or SLP?

Do analysts prefer QTRX or SLP?

Does the media refer more to QTRX or SLP?

Do insiders and institutionals have more ownership in QTRX or SLP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTRX vs. The Competition

Quanterix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools